1.21

0.41% -0.005

Reviva Pharmaceuticals Holdings Inc (RVPH)

Overview News Price History Option Chain Financials Discussions Forecast

Reviva Pharmaceuticals Holdings Inc stock is traded at $1.21, with a volume of 121.72K. It is down -0.41% in the last 24 hours and down -19.33% over the past month. Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

Previous Close:

$1.215

Open:

$1.2

24h Volume:

121.72K

Relative Volume:

0.26

Market Cap:

$41.80M

Revenue:

Net Income/Loss:

$-37.65M

P/E Ratio:

-0.8582

EPS:

-1.41

Net Cash Flow:

$-24.14M

1W Performance:

+0.00%

1M Performance:

-19.33%

6M Performance:

-7.28%

1Y Performance:

-72.87%

1-Day Range:

$1.18

$1.2299

1-Week Range:

$1.0909

$1.37

52-Week Range:

$0.60

$5.67

Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile

Name

Reviva Pharmaceuticals Holdings Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

(408) 501-8881

Address

10080 N WOLFE ROAD, CUPERTINO

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

RVPH's Discussions on Twitter

Compare RVPH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RVPH	1.21	41.80M	0	-37.65M	-24.14M	-1.41
VRTX	448.16	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	745.35	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	592.97	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	249.15	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.82	24.49B	3.30B	-501.07M	1.03B	11.54

Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-24-22	Initiated	H.C. Wainwright	Buy

Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Latest News

Nov 15, 2024

ARMISTICE CAPITAL, LLC Acquires New Stake in Reviva Pharmaceuticals Holdings Inc - GuruFocus.com

Nov 15, 2024

Schonfeld Strategic Advisors LLC Increases Stake in Reviva Pharm - GuruFocus.com

Nov 15, 2024

Reviva Pharmaceuticals Holdings Inc. Warrants (RVPHW) Quarterly 10-Q Report - Quartzy

Nov 15, 2024

Nov 14, 2024

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire

Nov 14, 2024

Reviva Pharma: 108 Patients Complete 1-Year Schizophrenia Drug Trial as Losses Narrow | RVPH Stock News - StockTitan

Nov 14, 2024

Reviva reports progress in schizophrenia treatment study By Investing.com - Investing.com Australia

Nov 14, 2024

Nov 12, 2024

Reviva reports progress in schizophrenia treatment study - Investing.com

Nov 12, 2024

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia - GlobeNewswire

Nov 12, 2024

Reviva's Brilaroxazine Hits Key Milestone: 108 Patients Complete 1-Year Schizophrenia Trial | RVPH Stock News - StockTitan

Nov 12, 2024

Nov 06, 2024

Reviva to Present Positive Speech Latency Data for - GlobeNewswire

Nov 06, 2024

Reviva Pharma to Present Breakthrough Phase 3 Schizophrenia Drug Data at CNS Summit | RVPH Stock News - StockTitan

Nov 06, 2024

Oct 31, 2024

Reviva to Participate in the UBS Global Healthcare Conference - GlobeNewswire

Oct 31, 2024

Oct 18, 2024

Reviva To Report Long-Term Safety Data For Brilaroxazine In Schizophrenia: Will The Stock Recover? - RTTNews

Oct 18, 2024

Oct 09, 2024

Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies | DelveInsight - GlobeNewswire Inc.

Oct 09, 2024

Oct 08, 2024

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit - The Manila Times

Oct 08, 2024

Oct 07, 2024

Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst - Benzinga

Oct 07, 2024

Oct 02, 2024

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - GlobeNewswire

Oct 02, 2024

Sep 26, 2024

Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference - The Manila Times

Sep 26, 2024

Sep 23, 2024

CA Pharma Co. Reports Positive Phase 3 Data for Schizophrenia Treatment - Streetwise Reports

Sep 23, 2024

Sep 18, 2024

RVPH’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle

Sep 18, 2024

Market Momentum: Reviva Pharmaceuticals Holdings Inc. (RVPH) Registers a 9.40 Increase, Closing at 1.28 - The Dwinnex

Sep 18, 2024

Sep 16, 2024

RVPH: RECOVER Biomarker KOL Event - Yahoo Finance

Sep 16, 2024

Sep 13, 2024

Closing Strong: Reviva Pharmaceuticals Holdings Inc. (RVPH) Ends at 1.12, Down -13.85 from Last Close - The Dwinnex

Sep 13, 2024

Sep 10, 2024

A stock that deserves closer examination: Reviva Pharmaceuticals Holdings Inc. (RVPH) - US Post News

Sep 10, 2024

Sep 09, 2024

Reviva reports positive schizophrenia trial results - Investing.com India

Sep 09, 2024

Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia - GlobeNewswire

Sep 09, 2024

Sep 04, 2024

How to interpret Reviva Pharmaceuticals Holdings Inc. (RVPH)’s stock chart patterns - US Post News

Sep 04, 2024